Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease

American Journal of Dermatopathology

Volumn 29, Issue 1, 2007, Pages 1-6

  Bridge, Andrew T ^a   Nelson Jr , Robert P ^a   Schwartz, Jennifer E ^a   Mirowski, Ginat W ^b   Billings, Steven D ^a,c  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF DENTISTRY   (United States)

^c Department of Pathology and Laboratory Medicine ^*  (United States)

Author keywords

Dermatopathology; Graft versus host disease; Nonmyeloablative hematologic stem cell transplant

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LICHENOID; LYMPHOMA; MALE; MYELODYSPLASTIC SYNDROME; MYELOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SKIN GRAFT;

ADULT; AGED; BIOPSY; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN; SKIN DISEASES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33846893396     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.dad.0000246173.96318.0c     Document Type: Article

References (35)

1. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
2. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531-4536.
3. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
4. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.
5. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620-1629.
6. Rao K, Amrolia PJ, Jones A, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood. 2005;105:879-885.
7. Shimoni A, Nagler A. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience. Curr Hematol Rep. 2004;3:242-248.
8. Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2004;10:178-185.
9. Slavin RE, Santos GW. The graft versus host reaction in man after bone marrow transplantation: pathology, pathogenesis, clinical features, and implication. Clin Immunol Immunopathol. 1973;1:472-498.
10. Shulman HM, Sale GE, Lerner KG, et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol. 1978;91:545-570.
11. Horn TD, Zahurak ML, Atkins D, et al. Lichen planus-like histopathologic characteristics in the cutaneous graft-vs-host reaction. Prognostic significance independent of time course after allogeneic bonemarrowtransplantation. Arch Dermatol. 1997;133:961-965.
12. Hood AF, Soter NA, Rappeport J, et al. Graft-versus-host reaction. Cutaneous manifestations following bone marrow transplantation. Arch Dermatol. 1977;113:1087-1091.
13. Farmer ER. Human cutaneous graft-versus-host disease. J Invest Dermatol. 1985;85:124s-128s.
14. Lerner KG, Kao GF, Storb R, et al. Histopathology of graft-vs-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc. 1974;6:367-371.
15. Horn TD, Bauer DJ, Vogelsang GB, et al. Reappraisal of histologic features of the acute cutaneous graft-versus-host reaction based on an allogeneic rodent model. J Invest Dermatol. 1994;103:206-210.
16. Massi D, Franchi A, Pimpinelli N, et al. A reappraisal of the histopathologic criteria for the diagnosis of cutaneous allogeneic acute graft-vs-host disease. Am J Clin Pathol. 1999;112:791-800.
17. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
18. Rappeport J, Mihm M, Reinherz E, et al. Acute graft-versus-host disease in recipients of bone-marrow transplants from identical twin donors. Lancet. 1979;2:717-720.
19. Hood AF, Vogelsang GB, Black LP, et al. Acute graft-vs-host disease. Development following autologous and syngeneic bone marrow transplantation. Arch Dermatol. 1987;123:745-750.
20. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756-762.
21. Flowers ME, Traina F, Storer B, et al. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. Bone Marrow Transplant. 2005;35:277-282.
22. Diez-Campelo M, Perez-Simon J, Martino R. Influence of the Intensity of the Conditioning Regimen on the Characteristics of Acure and Chronic Graft Versus Host Disease after Allogenic Transplantation. Blood. 2004;104.
23. Burroughs L, Storb R. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease. Curr Opin Hematol. 2005;12:45-54.
24. Valks R, Fernandez-Herrera J, Bartolome B, et al. Late appearance of acute graft-vs-host disease after suspending or tapering immunosuppressive drugs. Arch Dermatol. 2001;137:61-65.
25. Kohler S, Hendrickson MR, Chao NJ, et al. Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. Am J Surg Pathol. 1997;21:988-996.
26. Antin J, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964-2968.
27. Hill R, Petersen FB, Storb R, et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood. 1986;67:811-816.
28. Beard JS, Smith KJ, Skelton HG. Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease. J Am Acad Dermatol. 1993;29:325-330.
29. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
30. Nghiem P. The "drug vs graft-vs-host disease" conundrum gets tougher, but there is an answer: the challenge to dermatologists. Arch Dermatol. 2001;137:75-76.
31. Marra DE, McKee PH, Nghiem P. Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease. J Am Acad Dermatol. 2004;51:543-546.
32. Horn TD, Haskell J. The lymphocytic infiltrate in acute cutaneous allogeneic graft-versus-host reactions lacks evidence for phenotypic restriction in donor-derived cells. J Cutan Pathol. 1998;25:210-214.
33. Kuykendall TD, Smoller BR. Lack of specificity in skin biopsy specimens to assess for acute graft-versus-host disease in initial 3 weeks after bone-marrow transplantation. J Am Acad Dermatol. 2003;49:1081-1085.
34. Zhou Y, Barnett MJ, Rivers JK. Clinical significance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation. Arch Dermatol. 2000;136:717-721.
35. Barksdale SK, Oberlender SA, Barnhill RL. "Rush" skin biopsy specimens in a tertiary medical center: diagnostic yield and clinical utility. J Am Acad Dermatol. 1998;38:548-554.